Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 23, Issue 9, Pages 1290-1299Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajt.2023.05.010
Keywords
kidney transplant; regulatory; xenotransplantation
Categories
Ask authors/readers for more resources
The US FDA held a meeting to discuss regulatory expectations for xenotransplantation products, and a summary was compiled by a committee, focusing on 7 key topics including preclinical evidence, porcine kidney function, ethical aspects, clinical trial design, infectious disease issues, industry perspectives, and regulatory oversight.
In June 2022, the US Food and Drug Administration Center for Biologics Evaluation and Research held the 73rd meeting of the Cellular, Tissue, and Gene Therapies Advisory Committee for public discussion of regulatory expectations for xenotransplantation products. The members of a joint American Society of Transplant Surgeons/American Society of Transplantation committee on xenotransplantation compiled a meeting summary focusing on 7 topics believed to be key by the committee: (1) preclinical evidence supporting progression to a clinical trial, (2) porcine kidney function, (3) ethical aspects, (4) design of initial clinical trials, (5) infectious disease issues, (6) industry perspectives, and (7) regulatory oversight.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available